There is a faction on another public forum site who are bent on the idea that there are no catalysts left for AUPH until the end of the phase 3 trial in a few years. thats incorrect as we have learned from other companies like ARIA...remember when Ariad brought on a women by the name Ms Soni to the board? She had expertise in biotech deals and used to work at Takeda (shocking) I remember the stock really started to move after that appointment. It wasn't some overnight burst but an upward trend and higher daily volume along with excitement about Brig and expanded Pona development. My point is that turned out to be a catalyst that wasn't surrounding a science conference or announcement. We can expect plenty of events to occur with AUPH. Lets face the facts, AUPH has fantastic science and very recent findings. no competition out there, and a management team experienced with execution,deals,and buyouts
If folks think these gents are sitting around picking their noses bored waiting for the next results on Voclosporin. you are greatly mistaken.
So the AUPH Board of Directors is dripping with Merger and Acquisition talent. lets review as its pretty hilarious how obvious this company is for sale
We all know the first--> Richard Glickman. He needs no introduction for folks like us who listen into the webcasts. This dude knows the business and is well aware of the position he has the company in at this point. Former Founder and CEO of Aspreva Pharma who developed CellCept- the current standard of care for Lupus Nephritis. Aspreva Pharma was acquired by Galenica in 2008.
We have Lorin "Jeff" Randall with over 30 years experiences with biotech financials, he has "led a number of companies through multi-million dollar financings, mergers and acquisitions
There's Gregory Ayers MD PhD who was a venture partner for MPM Capital when he founded CryoCor (NASDAQNM:CRYO)...CryoCor was bought by Boston Scientific in 2007. He served on the Board of Hemosense which was bought by Inverness Medical and prior to all of this he was VP of clinical affairs for INcontrol which was bought by Guidant in the late 90's.
Don't forget Dr David Jayne who appears to be a world authority on all things lupus as well as a medical advisor to the UK, US, and EU Regulatory Bodies from a certified nephrology standpoint...
Then we have the final two recent appointments which are really exciting! lets see...
There's Hyuek Joon Lee Phd- this dude knows what he is doing for sure. Currently he is Director of New Business Development for ILJIN group. (we know who they are!) For ILJIN he is "responsible for mergers and acquisitions and managing overseas investments, joint ventures and subsidiaries."
Finally we have Ben Rovinski Phd. He's one of my favorites. why? well he is an ole chap from Lumira Capital. (we know who they are). Glick is a partner at Lumira as well. Ben has an investment focus on mid-to-late stage life science companies. "His current and past board roles and investment responsibilities include several companies, including KAI Pharma (acquired by AMGEN); Morphotek (acquired by Eisai); Health Hero Network (acquired by Bosch); Avalon Pharma (acquired by Clinical Data inc); SGX Pharma (acquired by Eli Lilly). among other companies. this guy has made deals after deals after deals after deals
When you doubt your investment just re-read my synopsis here and ask yourself how many times I had to type " bought by" or "acquired by"
I can tell you this, this Board was assembled for a reason folks
